Cell Lines
|
V
γ
9V
δ
2 CTL Expansion from PBMC/Number of Donors Tested
|
---|
DAUDI | 3/3 |
OCI-Ly8 | 0/3 |
L428 | 2/3 |
DG75 | 0/2 |
VAL | 0/3 |
RPMI8226 | 3/3 |
BL9 | 0/2 |
HLY-1 | 0/2 |
PASC | 0/2 |
DEAU | 2/3 |
NCI-H 929 | 0/2 |
RL | 0/3 |
LIB | 0/2 |
REC1 | 0/2 |
MIEUL | 0/2 |
RAJI | 0/3 |
- After 13-day co-culture of primary PBMC from healthy donors with irradiated NHL-cells, viable CD3+TCR-Vδ2+ cells were quantified by FACS. Amplification was considered negative when percentage of CD3+TCRVδ2+ cells in co-cultures was similar to that of PBMC cultured with IL-2 only. For each NHL, data summarize the ratio of amplification-reactive donors versus number of donors tested. For example, with the stimulating NHL DEAU, representative percentages of CD3+TCRVδ2+ cells are: donor 1, 9.9% in co-culture versus 3.1% for IL-2 alone; donor 2, 3.8% in co-culture versus 2.4% for IL-2 alone; donor 3, 18.1% in co-culture versus 2.8% for IL-2 alone. With nonstimulating NHL DG75: representative percentages of CD3+TCRVδ2+ cells are donor 1, 2.1% in co-culture versus 3.1% for IL-2 alone; donor 2, 1.1% in co-culture versus 2.4% for IL-2 alone.